BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 1358438)

  • 1. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.
    Saxena A; Clark WC; Robertson JT; Ikejiri B; Oldfield EH; Ali IU
    Cancer Res; 1992 Dec; 52(23):6716-21. PubMed ID: 1358438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
    Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours.
    Chattopadhyay P; Rathore A; Mathur M; Sarkar C; Mahapatra AK; Sinha S
    Oncogene; 1997 Aug; 15(7):871-4. PubMed ID: 9266974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
    Fults D; Brockmeyer D; Tullous MW; Pedone CA; Cawthon RM
    Cancer Res; 1992 Feb; 52(3):674-9. PubMed ID: 1346255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
    Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
    Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.
    Frankel RH; Bayona W; Koslow M; Newcomb EW
    Cancer Res; 1992 Mar; 52(6):1427-33. PubMed ID: 1347252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic deletion on chromosome 17p13.3 in early ovarian cancer.
    Phillips NJ; Ziegler MR; Radford DM; Fair KL; Steinbrueck T; Xynos FP; Donis-Keller H
    Cancer Res; 1996 Feb; 56(3):606-11. PubMed ID: 8564979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
    Cote RJ; Jhanwar SC; Novick S; Pellicer A
    Cancer Res; 1991 Oct; 51(19):5410-6. PubMed ID: 1913660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma.
    Nishida N; Fukuda Y; Kokuryu H; Toguchida J; Yandell DW; Ikenega M; Imura H; Ishizaki K
    Cancer Res; 1993 Jan; 53(2):368-72. PubMed ID: 8093350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genetic alterations in the region of the p53 gene on human chromosome 17 in colorectal cancer].
    Kashkin KN; Fleĭshman EV; Chumakov PM; Perevoshchikov AG
    Genetika; 1998 Aug; 34(8):1049-55. PubMed ID: 9777351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas.
    Jin W; Xu X; Yang T; Hua Z
    Chin Med J (Engl); 2000 Jul; 113(7):662-6. PubMed ID: 11776043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers.
    Sakamoto T; Nomura N; Mori H; Wake N
    Gynecol Oncol; 1996 Nov; 63(2):173-9. PubMed ID: 8910623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
    Lang FF; Miller DC; Koslow M; Newcomb EW
    J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
    Lerman MI; Minna JD
    Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors.
    Tsao SW; Mok CH; Oike K; Muto M; Goodman HM; Sheets EE; Berkowitz RS; Knapp RC; Lau CC
    Anticancer Res; 1991; 11(6):1975-82. PubMed ID: 1776830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers.
    Konishi H; Takahashi T; Kozaki K; Yatabe Y; Mitsudomi T; Fujii Y; Sugiura T; Matsuda H; Takahashi T; Takahashi T
    Oncogene; 1998 Oct; 17(16):2095-100. PubMed ID: 9798680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
    McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
    J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma.
    Adesina AM; Nalbantoglu J; Cavenee WK
    Cancer Res; 1994 Nov; 54(21):5649-51. PubMed ID: 7923211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus.
    Okamoto A; Sameshima Y; Yamada Y; Teshima S; Terashima Y; Terada M; Yokota J
    Cancer Res; 1991 Oct; 51(20):5632-5. PubMed ID: 1913680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization.
    Kobayashi M; Kawashima A; Mai M; Ooi A
    Am J Pathol; 1996 Nov; 149(5):1575-84. PubMed ID: 8909247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.